Search company, investor...

ActivX Biosciences

activx.com

Founded Year

2000

Stage

Acquired | Acquired

Total Raised

$26M

Valuation

$0000 

About ActivX Biosciences

ActivX Biosciences was a Healthcare/Biotechnology company based in La Jolla, California. ActivX Biosciences was acquired in 2005.

Headquarters Location

11025 North Torrey Pines Road Suite 120

La Jolla, California, 92037,

United States

858-558-5558

Missing: ActivX Biosciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: ActivX Biosciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest ActivX Biosciences News

ActivX Biosciences reports key findings that could impact the use of clinically approved CDK4/6 inhibitors in the treatment of cancer patients

Mar 11, 2019

| Source: ActivX Biosciences LA JOLLA, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- ActivX Biosciences, Inc., a wholly-owned subsidiary of Kyorin Pharmaceutical Co., Ltd. (Tokyo), announces a report published in a high profile, peer-reviewed journal, Molecular Cancer Therapeutics, ( http://mct.aacrjournals.org/content/early/recent?utm_source=early&utm_medium=dropdown&utm_campaign=menu ) proposing the molecular mechanism determining the sensitivity or resistance to treatment with CDK4/6 inhibitors. The CDK4/6 inhibitors palbociclib (Ibrance®, Pfizer), ribociclib (Kisqali®, Novartis) and abemaciclib (Verzenio®, Lilly) are approved for the treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. While these drugs have demonstrated clinical efficacy, there remains a need for biomarkers to predict patient response as well as to extend the use of these drugs beyond ER-positive breast cancer. Scientists at ActivX Biosciences, and their collaborators at Vall d’Hebron Institute of Oncology (VHIO), Barcelona, showed that high levels of p16/CDKN2A, an endogenous regulator of CDK4/6, could serve as a biomarker to identify patients unlikely to respond to CDK4/6 inhibitors, thus sparing them from unnecessary treatment. Using the KiNativ® platform, the authors assessed CDK4/6 target engagement in a panel of cell lines with known alterations in p16-CDK4 binding and showed that the interaction between p16 and CDK4 limits target engagement by CDK4/6 inhibitor drugs. Further research demonstrated that high levels of p16 were correlated with a lack of biological response in a diverse panel of cell lines that included the highly aggressive triple-negative breast cancer subtype. “We believe our findings will help define patient selection criteria for future clinical trials and extend the therapeutic benefits of these important drugs to patients with other types of cancer,” commented Jennifer Green, lead author of the study. "Identifying mechanisms for cell type-specific target engagement showcases the power of our technology. I’m excited to see what other examples are uncovered as the method is more broadly utilized.” The KiNativ platform, operated by ActivX, provides an unrivaled ability to quantitatively profile kinase inhibitors against native kinases in virtually any cell or tissue lysate. It is currently utilized by over 90 pharmaceutical/biotech companies and academic institutions. To learn more about KiNativ and its applications, go to www.kinativ.com  or call ActivX Biosciences at 858 526-2515. About ActivX Biosciences, Inc. ActivX Biosciences, Inc. ( www.activx.com ) located in La Jolla, California, is a wholly-owned subsidiary of Tokyo-based Kyorin Pharmaceutical Co. Ltd, and has drug discovery and proteomics technology capabilities. The company applies proprietary chemical technologies and high-throughput protein analysis to the drug discovery and development process. By focusing on functional proteins, ActivX® addresses disease mechanisms directly, in contrast to approaches such as expression profiling, in which the measured analyte is several steps removed from the site of drug action. ActivX® and its partners are using ActivX's proprietary technology to address critical challenges in drug discovery, including selectivity profiling of candidate drug molecules across whole protein families in biological samples to guide their medicinal chemistry efforts, identifying novel drug targets and biomarkers, and characterizing off-target activities of candidate and established drugs to understand the basis of their efficacy and/or toxicity. Related Articles

ActivX Biosciences Frequently Asked Questions (FAQ)

  • When was ActivX Biosciences founded?

    ActivX Biosciences was founded in 2000.

  • Where is ActivX Biosciences's headquarters?

    ActivX Biosciences's headquarters is located at 11025 North Torrey Pines Road, La Jolla.

  • What is ActivX Biosciences's latest funding round?

    ActivX Biosciences's latest funding round is Acquired.

  • How much did ActivX Biosciences raise?

    ActivX Biosciences raised a total of $26M.

  • Who are the investors of ActivX Biosciences?

    Investors of ActivX Biosciences include KYORIN, Oxford Bioscience Partners, Cercano Management, Frazier Healthcare Partners, Novo Holdings and 4 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.